Commercial Formulation • Improved manufacturability • Increased ease of dosing & safety • Maintenance of dose & potency • Maintenance of signature durability and • Improved immediacy The commercial formulation is designed to confer several key benefits: To fix the immediacy gap, we add free protein and conjugated protein to the commercial formulations for tarcocimab and KSI-501 24 70% Conjugated 30% Unconjugated (Free Protein) 5 mg 4 mg 1 mg Strength (Total Anti-VEGF antibody) Amount of Conjugated Protein Amount of Free Protein 80% Conjugated 20% Unconjugated (Free Protein) Tarcocimab KSI-501 5 mg 3.5 mg 1.5 mg